26 May 2025 in The Annals of Thoracic Surgery
13 October 2025 in Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery
Objective: Pediatric mitral valve replacement remains a significant challenge due to the lack of growth-capable prostheses, often necessitating multiple reoperations. Partial heart transplantation (PHT) has shown promise in the semilunar position but has not been studied in the atrioventricular (AV) position. This study evaluates the feasibility and growth potential of AV PHT in an in vivo porcine model. Methods: Three Yorkshire piglets underwent AV PHT, with the donor mitral valve implanted into the tricuspid position due to animal intraoperative tolerance limitations. The first 2 animals were used to refine surgical technique. The third piglet was designated for 2-month survival with serial echocardiographic monitoring. Donor valves were procured on the day of surgery to minimize ischemic time. Postoperative immunosuppression included tacrolimus, mycophenolate mofetil, and methylprednisolone. Results: The survival animal tolerated the procedure well and remained clinically stable. Echocardiography demonstrated significant growth of the PHT mitral annulus from 2.0 cm to 4.3 cm, compared with 2.4 cm to 3.0 cm in the native annulus. The length of the PHT leaflet increased from 1.3 cm to 2.4 cm, whereas the length of the native leaflet increased from 1.1 cm to 1.9 cm. Nonprogressive moderate regurgitation was observed without stenosis. Gross examination confirmed excellent tissue integration without calcification or fibrosis. Conclusions: This study demonstrates the in vivo feasibility and growth potential of AV PHT, representing a promising step toward growth-capable valve replacement for pediatric patients with irreparable mitral valve disease.
1 September 2025 in Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery
13 November 2025 in European Journal of Cardio-Thoracic Surgery
Objectives: Women patients with aortic stenosis (AS) exhibit distinct anatomic and physiologic features that may influence outcomes after valve replacement. While transcatheter aortic valve replacement (TAVR) has shown early advantages over surgical aortic valve replacement (SAVR) in women, long-term sex-specific outcomes remain unclear. To evaluate outcomes at 5 years comparing TAVR versus SAVR a systematic review and meta-analysis was performed. Methods: A systematic literature review was conducted, identifying all randomized controlled trials (RCTs) comparing TAVR with SAVR which included women with completed 5-year follow-up. The primary outcome was the composite of all-cause mortality or disabling stroke. Meta-analysis was performed using both random-effects and fixed-effect models. The study protocol was registered in PROSPERO (CRD420251004394). Results: Six RCTs were included with a total of 3094 women (1587 TAVR and 1507 SAVR). Overall, no significant difference was observed in the primary outcome between TAVR and SAVR (incidence rate ratios [IRRs] 1.00, 95% confidence interval [CI]: 0.88-1.13, P = .98). Meta-regression did not find any association between key clinical covariates and the primary outcome. Trial sequential analysis demonstrated that the extracted sample size met the required information size, but a definitive treatment effect was not confirmed. Conclusions: While TAVR shows an advantage over SAVR at 1-year follow-up in women, all-cause mortality or disabling stroke is similar in TAVR and SAVR at 5 years. Future studies must include sex-disaggregated reporting of both primary and secondary outcomes in order to comprehensively weigh risks and benefits of each intervention and inform personalized treatment strategies. Clinical registration number: The study protocol was registered in PROSPERO (CRD420251004394).
21 August 2025 in JHLT Open
We report the first US pediatric heart transplant utilizing the XVIVO Heart Assist Transport (XHAT) system for donor heart preservation. An 11-year-old recipient successfully received a heart from a 27-year-old donor using hypothermic ex vivo perfusion. The transplant was uncomplicated, with excellent 6-month outcomes. This case highlights the potential of XHAT to expand donor access and improve preservation in pediatric heart transplantation.
28 September 2026 in Pediatric Transplantation